foxo4 dri peptide senolytic skin FOXO4-DRI: A Breakthrough Targeting Aging at Its Roots FOXO4-DRI: Human Trial Status, Cancer

This is most relevant in patients with pernicious anaemia receiving initial replacement therapy and requires monitoring of electrolytes

It is used clinically and in research for tissue repair, with studies covering tendon and ligament injury, muscle strain, gut lining damage (including ulcers and inflammatory bowel conditions), and post-surgical recovery

The STEP 2 trial [2] , which included participants with type 2 diabetes, showed slightly more modest but still substantial results, with 9.6% average weight loss compared to 3.4% with placebo

It works by blocking an enzyme called NNMT, which slows down metabolism and fat burn